In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects

作者：Jones Ronald N^*; Biedenbach Douglas J; Sader Helio S

来源：Diagnostic Microbiology and Infectious Disease, 2009, 63(3): 339-341.

DOI：10.1016/j.diagmicrobio.2008.04.002

• Iclaprim
• N. gonorrhoeae
• Resistance
• STD

Iclaprim is a novel diaminopyrimidine currently in phase III clinical development. This study was conducted to determine the activity of iclaprim compared with trimethoprim and other commonly prescribed drug classes against a comprehensive collection of 156 Neisseria gonorrhoeae, including subsets of organisms resistant to beta-lactam and fluoroquinolones (> 60%). Iclaprim (MIC(50/90), 4/8 mu g/mL) was 16-fold more potent than trimethoprim (MIC(50/90), 64/> 04 mu g/mL), and medium growth supplements did not adversely influence activity. Lack of cross-resistances for iclaprim with other commonly used therapies could make iclaprim an alternative for several sexually transmitted diseases (gonococci, Chlamydia trachomatis).

• 出版日期2009-3